Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer [Yahoo! Finance]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
Founding CEO Marc Robillard, Ph.D., will continue in role of Chief Scientific Officer and as a member of the Board NIJMEGEN, Netherlands and BOSTON Oct. 1, 2024 /CNW/ -- Tagworks Pharmaceuticals BV ("Tagworks"), a precision oncology company using its proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies, today announced the appointment of Ken Mills as Chief Executive Officer and member of the Board of Directors. As part of this planned CEO leadership transition, Marc Robillard , Ph.D., the founding CEO of Tagworks, will continue in the role of Chief Scientific Officer and as a board member. Mr. Mills most recently served as Chief Executive Officer and President of REGENXBIO, which he founded and led for 15 years and where he continues as Chairman of the Board. Dr. Robillard founded Tagworks and has led the
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at HC Wainwright from $40.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.MarketBeat
- REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA [Yahoo! Finance]Yahoo! Finance
- REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATAPR Newswire
- REGENXBIO Inc. (NASDAQ: RGNX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $22.00 price target on the stock.MarketBeat
RGNX
Earnings
- 11/6/24 - Miss
RGNX
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/6/24 - Form 10-Q
- RGNX's page on the SEC website